Despite recent progress in developing treatments for dilated cardiomyopathy (DCM), mortality remains high. Given that insulin-like growth factor-1 (IGF1) improves myocardiocyte function in other pathological settings, Touvron et al. investigated whether IGF1 would also be beneficial in an established mouse model of DCM. The model involves cardiac-specific inducible knockout of serum response factor (*Srf*), encoding a transcription factor important for heart development and function; fatal DCM occurs within 10 weeks of inducing *Srf* deletion. Crossing these to mice that overexpress IGF1 in cardiomyocytes resulted in a strain that showed delayed DCM, better cardiac function and longer lifespan after *Srf* deletion. Overexpression of IGF1 also markedly reduced cardiac fibrosis and inflammation, partly by counteracting the increased expression of connective tissue growth factor (CTGF) caused by *Srf* deletion. These results further understanding of how *SRF* contributes to heart failure and suggest that IGF1 might be a promising therapeutic. **Page 481**
